Also, General Counsel Paul T. Quinlan sold 5,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Monday, October 16th.

Source: https://www.etfdailynews.com/2023/11/30/17700-shares-in-cymabay-therapeutics-inc-nasdaqcbay-acquired-by-boulder-hill-capital-management-lp/

As a group, research analysts anticipate that CymaBay Therapeutics will post -0.93 earnings per share for the current year.

Source: https://www.dailypolitical.com/2023/05/16/cymabay-therapeutics-inc-nasdaqcbay-short-interest-up-7-3-in-april.html

California State Teachers Retirement System bought a new stake in CymaBay Therapeutics in the first quarter valued at $649,000.

Source: https://www.americanbankingnews.com/2023/11/10/arizona-state-retirement-system-has-224000-stake-in-cymabay-therapeutics-inc-nasdaqcbay.html

Certain Stock Options of CymaBay Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2023.

Source: https://www.marketscreener.com/quote/stock/CYMABAY-THERAPEUTICS-INC-16725724/news/CymaBay-Submits-New-Drug-Application-to-FDA-for-Seladelpar-for-the-Treatment-of-Primary-Biliary-Chol-45579222/?utm_medium=RSS&utm_content=20231215

CM Management LLC raised its position in shares of CymaBay Therapeutics by 60.0% during the fourth quarter.

Source: https://www.etfdailynews.com/2023/02/10/cymabay-therapeutics-nasdaqcbay-price-target-increased-to-12-00-by-analysts-at-svb-leerink/

Finally, CTC Capital Management LLC bought a new position in CymaBay Therapeutics during the first quarter valued at $93,000.

Source: https://www.etfdailynews.com/2023/05/21/charles-mcwherter-sells-21749-shares-of-cymabay-therapeutics-inc-nasdaqcbay-stock/

HC Wainwright boosted their price target on shares of CymaBay Therapeutics from $10.00 to $12.00 in a research report on Friday, March 17th.

Source: https://www.etfdailynews.com/2023/04/18/cymabay-therapeutics-inc-nasdaqcbay-insider-sells-69873-38-in-stock/